The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 339:223-228 July 23, 1998 Number 4
NextNext

Micrometastases and Survival in Stage II Colorectal Cancer
Gerrit-Jan Liefers, M.D., Anne-Marie Cleton-Jansen, Ph.D., Cornelis J.H. van de Velde, M.D., Ph.D., Jo Hermans, Ph.D., Johannes H.J.M. van Krieken, M.D., Ph.D., Cees J. Cornelisse, Ph.D., and Rob A.E.M. Tollenaar, M.D., Ph.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Lindblom, A.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Standard treatment of colorectal cancer includes adjuvant chemotherapy for patients with stage III disease (defined by the presence of lymph-node metastases), but not for patients with stage II tumors (who have no lymph-node metastases). However, 20 percent of patients with stage II tumors die of recurrent disease. We investigated whether the detection of micrometastases can be used to identify patients with stage II disease who are at high risk for recurrence.

Methods We analyzed 192 lymph nodes from 26 consecutive patients with stage II colorectal cancer, using a carcinoembryonic antigen–specific nested reverse-transcriptase polymerase chain reaction. Five-year follow-up information was obtained on all patients. Observed and adjusted survival rates were assessed in the patients with and the patients without micrometastases.

Results Micrometastases were detected in one or more lymph nodes from 14 of 26 patients (54 percent). The adjusted five-year survival rate (for which only cancer-related deaths were considered) was 50 percent in this group, whereas in the 12 patients without micrometastases, the survival rate was 91 percent (P=0.02 by the log-rank test). The observed five-year survival rates were 36 percent and 75 percent, respectively (P=0.03). The groups were similar with respect to age, sex, tumor side (location in relation to the flexura lienalis), degree of tumor differentiation (grade), and diameter of the primary tumor.

Conclusions Molecular detection of micrometastases is a prognostic tool in stage II colorectal cancer.


Source Information

From the Department of Surgery (G.-J.L., C.J.H.V., R.A.E.M.T.), the Department of Pathology (A.-M.C.-J., J.H.J.M.K., C.J.C.), and the Department of Medical Statistics (J.H.), Leiden University Medical Center, Leiden, the Netherlands.

Address reprint requests to Dr. Tollenaar at the Department of Surgery K6R, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, the Netherlands.

Full Text of this Article


Related Letters:

Detection of Carcinoembryonic Antigen Messenger RNA in Lymph Nodes from Patients with Colorectal Cancer
Merrie A. E.H., Yun K., McCall J. L., Ghossein R. A., Bostick P. J., Hoon D. S.B., Cote R. J., Liefers G.-J., Cleton-Jansen A.-M., Tollenaar R. A.E.M.
Extract | Full Text  
N Engl J Med 1998; 339:1642-1644, Nov 26, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.